Stand Up To Cancer - standuptocancer.orgThis is where the end of cancer begins
   Please leave this field empty

SU2C Scientific Research Teams

Share this:

Like this page on Facebook

Anthony Letai, MD, PhD

Scientific Research Team:
Anthony Letai, MD, PhD

Anthony Letai, MD, PhD

The SU2C – National Science Foundation- V Foundation Drug Combination Convergence Translational Research

Dr. Letai received his M.D. and Ph.D. (under the direction of Elaine Fuchs) at the University of Chicago. He completed his clinical training in internal medicine at Brigham and Women’s Hospital in Boston, followed by a fellowship in hematology and oncology at Dana-Farber Cancer Institute. He was introduced to apoptosis and BCL-2 family proteins as a post-doctoral researcher in the laboratory of the late Stanley Korsmeyer. In 2004, Dr. Letai became an independent investigator at Harvard Medical School and the Dana-Farber Cancer Institute where he is now an associate professor in medicine. His laboratory studies how apoptosis can be evaded, particularly in cancer cells, and how this evasion may be detected and targeted. Key to these studies is a novel assay—BH3 profiling—that can detect the pathways being used by the cells to evade apoptosis and how close a cell is to the threshold of apoptosis, providing useful and clinically relevant information. He has also led efforts to translate BCL-2, BCL-XL, and MCL-1 inhibitors into the clinic, including in CLL, AML, ALL, and BPDCN. His lab is testing whether BH3 profiling can be used as a predictive biomarker in clinical cancer therapy.